Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00162240 · ClinicalTrials.gov registry record · Phase 3
PPAR - Combination With Metformin
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 534
- Enrollment target
NCT00162240: Completed Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT00162240 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 534 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (31% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00162240, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 534 participants
- Enrollment target
Study Summary
A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination with Metformin Therapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
Interventions
- DRUG Muraglitazar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 534 participants |
| Start Date | 2003-06 |
| Est. Completion | 2004-05 |
| Phase | Phase 3 |
What the finished NCT00162240 record still lists
NCT00162240 is an interventional study that assigns participants to a tested intervention. The registered 534 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (31% lower).
The record links to 0 conditions, and to 1 intervention - of which Muraglitazar is the first listed.
NCT00162240 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00162240 about?
NCT00162240 is a clinical study titled "PPAR - Combination With Metformin". A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination with Metformin Therapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
What is the current status of trial NCT00162240?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 534 participants. The study started on 2003-06. Estimated completion is 2004-05.
What interventions are being tested in trial NCT00162240?
The interventions under investigation include: Muraglitazar (DRUG).
Who is sponsoring clinical trial NCT00162240?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00162240's enrollment target sits among peer trials
534 703rd of 2000 higher than 1,297 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04910685 · 534 participants · Phase 2
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
- NCT06128551 · 534 participants · Phase 1
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- NCT05614739 · 535 participants · Phase 1
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
- NCT07091617 · 535 participants · NA
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia